Kyu Tae Byun

Oct 16, 2023 | onlinelibrary.wiley.com | Kyu Tae Byun |Seung Han Son |Sungwoo Choi |Ji Kim

1 Introduction Despite significant advancements in molecular and cancer biology, which have led to revolutionary changes in cancer treatment paradigms and the development of sophisticated anticancer therapeutics, cancer continues to be a major global public health problem. This is primarily due to tumor heterogeneity and the likelihood of later recurrence.

Oct 16, 2023 | pericles.pericles-prod.literatumonline.com | Kyu Tae Byun |Seung Han Son |Sungwoo Choi |Ji Kim

1 Introduction Despite significant advancements in molecular and cancer biology, which have led to revolutionary changes in cancer treatment paradigms and the development of sophisticated anticancer therapeutics, cancer continues to be a major global public health problem. This is primarily due to tumor heterogeneity and the likelihood of later recurrence.

Oct 11, 2023 | mdpi.com | K. Tae |Boram Kim |Junmin Cho |Kyu Tae Byun

1. IntroductionSince hybridoma technology was developed in the mid-1970s, immunoglobulin G (IgG)-based monoclonal antibodies (mAbs) have served as an invaluable asset for developing antibody-based therapeutic and diagnostic agents for various diseases. Advances in recombinant protein technology have led to rapid progress in the application of antibody engineering, including antibody-drug conjugates (ADCs), bispecific antibodies (biAbs), and diverse scaffolds of antibody fragments (AbFs) [1,2,3,4].